ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

Gallo’s Lab Moved From DCT to DCE; NCI Planning To Drop “Cancer Treatment Reports” At End Of ‘86

February 6, 1987

Racial Differences In Survival Increase According To Stage

August 31, 2007

DCT Board Approves Concepts For New RFA, New And Recompeting Contracts

June 18, 1982

NCI Prepares To Dispense A Torrent Of New Money For Cancer Research.

March 6, 2009

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

Ethics Commission Acknowledges Weak Case For Mandatory Patient Compensation

April 23, 1982